Jean-Francois H Geschwind1, Julius Chapiro1. Show Affiliations » 1. Yale School of Medicine, New Haven, Connecticut.
Abstract
Entities: Chemical Disease
Mesh: See more » Antineoplastic Agents/administration & dosageAntineoplastic Agents/adverse effectsAntineoplastic Agents/therapeutic useCarcinoma, Hepatocellular/pathologyCarcinoma, Hepatocellular/therapyChemoembolization, Therapeutic/adverse effectsChemoembolization, Therapeutic/methodsClinical Decision-MakingClinical Trials as TopicCombined Modality TherapyDisease ManagementHumansLiver Neoplasms/pathologyLiver Neoplasms/therapyNeoplasm StagingNiacinamide/administration & dosageNiacinamide/adverse effectsNiacinamide/analogs & derivativesNiacinamide/therapeutic usePhenylurea Compounds/administration & dosagePhenylurea Compounds/adverse effectsPhenylurea Compounds/therapeutic useProtein Kinase Inhibitors/administration & dosageProtein Kinase Inhibitors/adverse effectsProtein Kinase Inhibitors/therapeutic useSorafenibTreatment Outcome
Substances: See more » Antineoplastic AgentsPhenylurea CompoundsProtein Kinase InhibitorsNiacinamideSorafenib
Year: 2016 PMID: 27487101
Source DB: PubMed Journal: Clin Adv Hematol Oncol ISSN: 1543-0790